NCT02227082View on ClinicalTrials.gov

Olaparib and Radiotherapy in Inoperable Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 21, 2013

Primary Completion Date

September 30, 2019

Study Completion Date

August 31, 2020

Conditions
Locally Advanced Malignant NeoplasmInflammatory Breast CarcinomaTriple-Negative Invasive Breast Carcinoma
Interventions
RADIATION

radiotherapy

The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy

DRUG

olaparib

The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID

Trial Locations (1)

1066 CX

The Netherlands Cancer Institute, Amsterdam

All Listed Sponsors
lead

The Netherlands Cancer Institute

OTHER

NCT02227082 - Olaparib and Radiotherapy in Inoperable Breast Cancer | Biotech Hunter | Biotech Hunter